JP2023515081A - 腎損傷を治療するための組成物および方法 - Google Patents

腎損傷を治療するための組成物および方法 Download PDF

Info

Publication number
JP2023515081A
JP2023515081A JP2022549924A JP2022549924A JP2023515081A JP 2023515081 A JP2023515081 A JP 2023515081A JP 2022549924 A JP2022549924 A JP 2022549924A JP 2022549924 A JP2022549924 A JP 2022549924A JP 2023515081 A JP2023515081 A JP 2023515081A
Authority
JP
Japan
Prior art keywords
alkyl
renal
injury
alkylene
pgdh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515081A5 (https=
Inventor
マルコウィッツ，サンフォード
ペ，キボム
ジュン キム，ヘ
キム，スン－ヒ
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
インジェ インダストリー アカデミック コーポレーション ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, インジェ インダストリー アカデミック コーポレーション ファウンデーション filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2023515081A publication Critical patent/JP2023515081A/ja
Publication of JP2023515081A5 publication Critical patent/JP2023515081A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022549924A 2020-02-21 2021-02-22 腎損傷を治療するための組成物および方法 Pending JP2023515081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979813P 2020-02-21 2020-02-21
US62/979,813 2020-02-21
PCT/US2021/019084 WO2021168430A1 (en) 2020-02-21 2021-02-22 Compositions and methods for treating renal injury

Publications (2)

Publication Number Publication Date
JP2023515081A true JP2023515081A (ja) 2023-04-12
JP2023515081A5 JP2023515081A5 (https=) 2024-03-01

Family

ID=77391654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549924A Pending JP2023515081A (ja) 2020-02-21 2021-02-22 腎損傷を治療するための組成物および方法

Country Status (7)

Country Link
EP (1) EP4106748A4 (https=)
JP (1) JP2023515081A (https=)
KR (1) KR20230011910A (https=)
AU (1) AU2021224268A1 (https=)
CA (1) CA3168728A1 (https=)
MX (1) MX2022010258A (https=)
WO (1) WO2021168430A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
TW202419452A (zh) * 2022-11-11 2024-05-16 大陸商賽諾哈勃藥業（成都）有限公司 調控１５－ｐｇｄｈ活性的化合物、其藥物組合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514770A (ja) * 2012-04-16 2015-05-21 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
JP2016537328A (ja) * 2013-10-15 2016-12-01 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
JP2018511581A (ja) * 2015-03-08 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
WO2019195565A1 (en) * 2018-04-04 2019-10-10 Case Western Reserve University Compositions and methods for treating renal injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016248080A1 (en) * 2015-04-14 2017-11-02 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514770A (ja) * 2012-04-16 2015-05-21 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
JP2016537328A (ja) * 2013-10-15 2016-12-01 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
JP2018511581A (ja) * 2015-03-08 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
WO2019195565A1 (en) * 2018-04-04 2019-10-10 Case Western Reserve University Compositions and methods for treating renal injury

Also Published As

Publication number Publication date
MX2022010258A (es) 2023-01-24
EP4106748A4 (en) 2024-02-28
KR20230011910A (ko) 2023-01-25
CA3168728A1 (en) 2021-08-26
EP4106748A1 (en) 2022-12-28
WO2021168430A1 (en) 2021-08-26
AU2021224268A1 (en) 2022-09-15
US20230052363A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
JP2023515081A (ja) 腎損傷を治療するための組成物および方法
US20250325524A1 (en) Compositions and methods for treating renal injury
JP2022521824A (ja) アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用
BRPI0415374B1 (pt) uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
JP2013518909A (ja) アロステリックキナーゼ阻害が関係する治療方法および組成物
TW201607943A (zh) 作為ｅｐ４配體之新穎苯并咪唑衍生物
JP2007509968A (ja) 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ
TWI640519B (zh) Ｈｅｃ１活性調控因子及其調節方法
CN103608014A (zh) 激酶抑制剂在治疗和预防炎症疾病中的用途
US11046657B2 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
JP5153621B2 (ja) Ｓｈｐ−２阻害剤、それらを含む薬剤組成物及びホスファターゼ媒介性疾患を治療するためのその使用
WO2018157801A1 (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
CN101478989A (zh) 炎性肠病的处置剂
US12616681B2 (en) Compositions and methods for treating renal injury
WO2002078705A1 (en) Hsp inductor
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体
ES2252398T3 (es) Derivados de 5-n-heterociclil-1-(4sulfonil-fenil)-1h-pirazol con actividad inhibidora de la ciclooxigenasa-2-(cox-2) para el tratamiento de enfermedades inflamatorias.
HK40052492A (en) Compositions and methods for treating renal injury
US20080090788A1 (en) Chemical Compounds
BR112016016386B1 (pt) Composto ou um sal ou solvato do mesmo, composição farmacêutica e uso de um composto na preparação de um medicamento
WO2023034644A2 (en) Methods of treatment using bcn057, bcn077 and analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930